
Roche: a new breast cancer treatment approved in the US
Keystone-SDA
Swiss pharmaceutical giant Roche is set to launch a new oral treatment for hormone-dependent breast cancer on the US market. It could generate up to CHF500 million ($592 million) as early as next year.
The US drug regulator, the Food and Drug Administration (FDA), has approved Wilserdly (giredestrant) in combination with everolimus for use in patients with oestrogen receptor (ER)-positive breast cancer, with HER2-negative status (human epidermal growth factor receptor 2) and an ESR1 gene mutation, in locally advanced or metastatic disease, according to a press release.
When contacted by the AWP news agency, the group said it expects the launch to contribute to the company’s sales from next year onwards, “with 2027 representing Wilserdly’s first full year on the market”.
The consensus estimate puts revenue in the range of $500-600 million, “which is in line with our expectations”. By way of comparison, Roche recorded revenue of CHF61.52 billion in 2025, of which CHF48 billion came from its pharmaceuticals division.
Analyst Urban Fritsche of Zurich Cantonal Bank (ZKB) estimates that the treatment could generate up to CHF14 billion in sales at its peak in 2033, while the consensus forecast stands at CHF4.2 billion.
Roche told AWP that the therapy is being marketed “at a list price of $22,500 per month”, while emphasising that this amount will not necessarily correspond to what patients will actually pay, depending on coverage by their insurance or public assistance schemes.
This price is on a par with the Inluriyo (imlunestrant) treatment from US competitor Eli Lilly, but is cheaper than Etcamah (camizestrant) from UK-based AstraZeneca, notes the Royal Bank of Canada (RBC) in a commentary.
More

More
How a clash with Roche exposed cracks in Swiss drug pricing system
Oral treatment
Roche states that the combination of Wilserdly and everolimus has significantly delayed disease progression or reduced mortality by 62% compared with standard endocrine therapy combined with everolimus.
In a separate document, the FDA emphasises that the treatment developed by Genentech, the Basel-based company’s US subsidiary, is intended for patients whose disease has recurred during or after completion of adjuvant endocrine therapy, or has progressed while on at least one endocrine therapy at the metastatic stage.
The FDA says that the prescribing information includes warnings and precautions concerning, in particular, embryo-foetal toxicity.
According to Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, quoted in the company’s document, “for patients with advanced breast cancer harbouring an ESR1 gene mutation, the development of resistance to hormone therapy remains a major challenge, often requiring more intensive treatment”.
He added, “Wilserdly offers a targeted, entirely oral treatment that significantly delays disease progression and enables patients with advanced breast cancer to continue their treatment from home”.
Teresa Graham, head of the pharmaceuticals division, who was also quoted, added that following decades of Roche’s work in oncology, “this first marketing authorisation for Wilserdly marks a decisive step forward in the management of aggressive, treatment-resistant breast cancer”.
The Swiss stock market heavyweight noted that 2.3 million women are diagnosed with breast cancer and 670,000 die from it each year worldwide, citing figures from the WHO. Hormone-dependent breast cancer accounts for 70% of cases.
More

More
Switzerland faces pressure from US drug pricing policy
+ How we produce news in English
Translated from French, reviewed by an English Department journalist.


